Harrow Launches Cash-Pay PharmaPack Kits for FDA-Approved Ophthalmic Therapies across Five States
Harrow launched PharmaPack, a cash-pay direct-to-prescriber service offering affordable, transparent-priced FDA-approved ophthalmic kits, expanding access for cataract surgery infection control and inflammation treatments. The program removes insurance-related administrative complexity, reduces regulatory and medical-legal risk from off-label compounding, and will debut in California, Mississippi, Arkansas, Connecticut and Alabama with nationwide expansion.
1. Harrow Unveils PharmaPack Program
Harrow introduced PharmaPack, a direct-to-prescriber cash-pay offering that delivers FDA-approved branded ophthalmic therapies as preassembled kits. This initiative targets the millions of patients undergoing cataract surgery who need reliable infection control and inflammation management without relying on compounded alternatives.
2. Cash-Pay Model Advantages
PharmaPack provides 100% transparent pricing, eliminating insurance-related administrative hurdles and lowering regulatory and medical-legal risks tied to off-label compounded formulations. The cash-pay structure aims to streamline prescribing and foster confidence in FDA-approved branded products among eye care professionals.
3. Initial Rollout and Expansion Strategy
PharmaPack kits will first be available in California, Mississippi, Arkansas, Connecticut and Alabama, with plans to expand nationwide in the coming weeks. Prescribers can order directly through their account dashboard or via Harrow representatives, positioning the company for broader market penetration.